Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Autolus Therapeutics (AUTL) over the last 5 years, with Sep 2025 value amounting to $52.3 million.

  • Autolus Therapeutics' Accumulated Expenses rose 10.06% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year increase of 10.06%. This contributed to the annual value of $52.3 million for FY2024, which is 32.07% up from last year.
  • As of Q3 2025, Autolus Therapeutics' Accumulated Expenses stood at $52.3 million, which was up 1.75% from $51.4 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Accumulated Expenses registered a high of $23.2 billion during Q2 2021, and its lowest value of $31,903 during Q4 2021.
  • Over the past 3 years, Autolus Therapeutics' median Accumulated Expenses value was $48.6 million (recorded in 2024), while the average stood at $45.7 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Accumulated Expenses crashed by 100.00% in 2022, and later spiked by 44.37% in 2025.
  • Over the past 5 years, Autolus Therapeutics' Accumulated Expenses (Quarterly) stood at $31,903 in 2021, then slumped by 99.86% to $40,859 in 2022, then reached $39.6 million in 2023, then skyrocketed by 32.07% to $52.3 million in 2024, then increased by 10.06% to $52.3 million in 2025.
  • Its Accumulated Expenses was $52.3 million in Q3 2025, compared to $51.4 million in Q2 2025 and $49.7 million in Q1 2025.